Current Studies: |
A Comparative Effectiveness Study of Intensive Glycemic Control vs. Less Intensive Control |
Joseph Selby, Principal Investigator
Gregory A. Nichols, Co-Investigator |
| Funding Source: Agency for Healthcare Research and Quality |
| Funding Period: September 2009–August 2011 |
| This study addressed the question of whether intensive glycemic control in adult patients with type 2 diabetes leads to improved short- and longer-term outcomes compared with less intensive therapy. The study also aimed to determine whether the benefit varies as a function of age, prior cardiovascular disease, blood pressure, or LDL-cholesterol control. |
|
|
| |
A Microfinance Intervention to Improve Health of Rape Survivors in the DRC—Micro DRC |
Nancy Glass, Principal Investigator
Nancy A. Perrin, Co-Investigator |
| Funding Source: National Center on Minority Health and Health Disparities through a subcontract with Johns Hopkins University |
| Funding Period: December 2010–November 2015 |
| This study evaluates a microfinance intervention with victims of domestic violence in Democratic Republic of the Congo. The study outcomes are collected at the individual, household, and community level with a focus on health, food security, school attendence, and health care utilization. |
|
|
| |
A Multi-level Intervention to Improve rates of Mammography Screening in Latinas; Centers for Population Health and Health Disparities |
Gloria Coronado, Principal Investigator
|
| Funding Source: National Cancer Institute |
| Funding Period: December 2009–November 2014 |
| The overall goal of this project (Understanding and preventing breast cancer disparities in Latino women) is to address the disparate burden of breast cancer among Latino women. Dr. Coronado is the project director on the clinic-based intervention study. |
|
|
| |
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety, and Tolerability of Zostavax in Subjects 50-59 years of Age—Zostavax |
Elizabeth Liles, Principal Investigator
Sheila Weinmann, Adrianne C. Feldstein, Co-Investigator |
| Funding Source: Merck & Co., Inc. |
| Funding Period: October 2007–January 2012 |
| This study evaluates Merck’s Zostavax herpes zoster (HZ) vaccine in the 50-59 year old population. It is a double blind randomized clinical trial with a 1:1 ratio of Zostavax to placebo. Patients will be seen in the research clinic for screening, randomization, and one in-person follow-up visit. They will be contacted by phone by CHR staff to assess for HZ and adverse events at 4- and 6-months. The patients will be contacted monthly for 12 months by an IVRS that will assess for HZ and adverse events. The CHR research clinic plans to enroll approximately 1,000 patients. |
|
|
| |
A Population-Based Study of TMEM and Breast Cancer Prognosis—TMEM Medstat |
Thomas Rohan, Principal Investigator
Andrew G. Glass, Co-Investigator |
| Funding Source: MEDTAP Institute |
| Funding Period: May 2011–April 2012 |
| We propose to evaluate human breast cancer samples, in a population based study, for the number of Tumor Microenvironment of Metastasis (TMEMs) as stained by this novel immunohistochemical method and correlate TMEM scores with metastatic outcome and survival. This study will be done in a retrospective analysis of archived breast cancer cases.
|
|
|
| |
A Social Technology to Maximize the Impact of a Regional Strategic Plan |
Carmit McMullen, Principal Investigator
|
| Funding Source: Kaiser Permanente Internal (Program Office) |
| Funding Period: October 2010–June 2011 |
| Within the project period, we will (1) create a valid contact list (sampling frame) for all KPNW physicians, staff, and employees; (2) collect sociometric data from an online survey of all KPNW individuals; (3) prepare Excel-based data files of two types for large-scale (N=approximately 4,000) analysis; (4) apply the social network analysis program InFloPro to these data and produce network-level, group-level, and individual-level estimates for a range of variables; and (5) present and train KPNW research personnel in the continued use of this new data-set for change management purposes.
|
|
|
| |
Alcohol use, survival, and quality of life at older ages: A prospective study |
David Feeny, CHR Investigator
|
| Funding Source: National Institute on Aging |
| Funding Period: 2/2010 - 1/2012 |
| This project addresses alcohol use and quality of life concerns using a nationally representative sample of Canadian adults (over age 50 at baseline) who have been surveyed about alcohol use and consequences biannually for 12 years. It also describes longitudinal patterns of alcohol use. |
|
|
| |
American Recovery and Reinvestment Act of 2009: Comprehensive EPC Comparative Effectiveness Reviews for Effective Health Care; Area of Concentration 7: Care Delivery (EPC ARRA) |
Mark A Helfand, Principal Investigator
Evelyn P. Whitlock, Xin Sun, Co-Investigators |
| Funding Source: Agency for Healthcare Research and Quality |
| Funding Period: October 2009–October 2012 |
| Establish a comprehensive center in comparative effectiveness research in Health Care Delivery, prevention, and behavioral interventions at the Oregon Evidence-based Practice Center in order to develop research topics, conduct comparative effectiveness systematic reviews, and develop future research agendas in these cross-cutting areas. |
|
|
| |
An Epidemiology Study of Changes in Rates of Opioid Overdose and Poisoning Events in the Kaiser Permanente Health System with the Introduction of Reformulated Oxycontin® |
Carla A. Green, Principal Investigator
Nancy A. Perrin, Co-Investigator |
| Funding Source: Purdue Pharma, L.P. |
| Funding Period: May 2011–April 2014 |
| This study tests the hypothesis that new tamper-resistant formulation of OxyContin will reduce the rate of adverse events related to overdose, and poisoning among patients prescribed OxyContin and, among those obtaining OxyContin without a prescription compared to events among individuals prescribed other opioids and, those using other opioids without prescriptions. |
|
|
| |
Analysis of CMI Patient Experience Survey |
David Mosen, Principal Investigator
Nancy A. Perrin, Co-Investigator |
| Funding Source: Kaiser Permanente |
| Funding Period: November 2010–June 2011 |
| The goal of the work covered by this agreement is to complete a secondary data analysis of the CMl Patient Experience Survey (PES). This project is a de-identified program evaluation analysis and is exempt from IRB review.
|
|
|
| |